Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)

Academic Article

Publication Date:

2016

Short description:

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) / Leone, ., Marino, ., Cereda, ., Filippi, ., Belli, ., Spadi, ., Nasti, ., Montano, ., Amatu, ., Aprile, ., Cagnazzo, ., Fasola, ., Siena, ., Ciuffreda, ., Reni, M., Aglietta,. - In: CANCER. - ISSN 1097-0142. - (2016).

Iris type:

1.1 Articolo in rivista

List of contributors:

Leone, ; Marino, ; Cereda, ; Filippi, ; Belli, ; Spadi, ; Nasti, ; Montano, ; Amatu, ; Aprile, ; Cagnazzo, ; Fasola, ; Siena, ; Ciuffreda, ; Reni, M; Aglietta,

Authors of the University:

RENI MICHELE

Handle:

https://iris.unisr.it/handle/20.500.11768/124059

Published in:

CANCER

Journal